Ecuador ARCSA Medical Device Registration Guide: New 2026 Regulations, Requirements, and Process

Overview of Ecuador's Medical Device Market

Ecuador is an increasingly important medical device market in the Andean region of Latin America. With a population of approximately 18 million, a growing healthcare infrastructure, and a public health system that relies heavily on imported medical technology, the country presents a meaningful opportunity for foreign manufacturers seeking to expand their Latin American footprint.

Several factors make Ecuador a market worth considering:

• Import-driven market — Ecuador imports the vast majority of its medical devices, with domestic manufacturing limited primarily to basic disposables and hospital supplies. This creates broad opportunities for international manufacturers across all device categories.
• Public procurement scale — Ecuador's public health system, including the Instituto Ecuatoriano de Seguridad Social (IESS) and the Ministry of Public Health (MSP), conducts significant centralized procurement of medical devices, creating large-volume purchasing opportunities.
• Andean Community membership — As a member of the Comunidad Andina de Naciones (CAN) alongside Colombia, Peru, and Bolivia, Ecuador participates in regional harmonization efforts that can facilitate multi-country regulatory strategies.
• Regulatory modernization — In April 2026, ARCSA signed sweeping new regulations that fundamentally update the medical device registration framework for the first time in a decade, introducing explicit provisions for AI/ML-enabled devices, mandatory technovigilance, and enhanced post-market controls.
• US-Ecuador trade cooperation — Under the 2025 US-Ecuador trade framework, ARCSA now accepts MDSAP audit reports from US facilities, streamlining the quality system evidence pathway for American manufacturers.

The medical device market in Ecuador is valued at approximately USD 840 million (2024), with projections suggesting growth to over USD 1 billion by 2028 at a compound annual growth rate (CAGR) of approximately 6.4%. The market continues to expand as the government invests in healthcare infrastructure modernization, hospital expansion, and improved access to diagnostic and therapeutic technologies across all regions of the country.

However, market access requires navigating ARCSA's registration process, which has been significantly updated by the new 2026 regulations. This guide covers every aspect of the current requirements so you can plan your market entry with confidence.

Regulatory Authority and Legal Framework

ARCSA — Ecuador's National Regulatory Authority

ARCSA — Agencia Nacional de Regulacion, Control y Vigilancia Sanitaria (National Agency for Health Regulation, Control, and Surveillance), formally bearing the full name "Agencia Nacional de Regulacion, Control y Vigilancia Sanitaria Dr. Leopoldo Izquieta Perez" — is Ecuador's national regulatory authority responsible for overseeing pharmaceuticals, medical devices, food products, cosmetics, and other health-related products.

Established in 2012, ARCSA consolidated regulatory functions that were previously dispersed across multiple government entities. The agency operates under the authority of Ecuador's Ministry of Public Health and is responsible for:

• Pre-market registration and evaluation of medical devices and IVDs
• Classification determination for all medical devices entering the Ecuadorian market
• Post-market surveillance and technovigilance including adverse event reporting, market surveillance inspections, and laboratory analysis
• Import and distribution control for medical devices
• Labeling and advertising oversight to ensure Spanish-language compliance and accurate claims
• Sanctions and enforcement for non-compliant products, manufacturers, and distributors

Legal Framework

Ecuador's medical device regulatory framework is built on multiple layers of legislation and regulation. The key instruments are:

Legislation / Regulation	Scope
Organic Health Law (Ley Organica de Salud)	Overarching health legislation establishing the regulatory framework for health products in Ecuador
Executive Decree No. 1583	Decree establishing ARCSA's mandate and organizational structure
Ministerial Agreement No. 0000230	Regulatory provisions for medical device registration and control
Ministerial Agreement No. 205	Additional provisions governing medical device commercialization
Resolution ARCSA-DE-026-2016-YMIH	Previous comprehensive medical device registration rules (replaced by 2026 regulations)
Resolution ARCSA-DE-030-2018-JCGO	Amendments to the 2016 resolution (now superseded)
New Resolution (April 28, 2026)	Sweeping new regulations replacing the 2016 framework, signed by Executive Director Dr. Daniel Antonio Sanchez Procel

The April 2026 resolution represents the most significant regulatory overhaul for medical devices in Ecuador in a decade. It modernizes the entire registration framework, introduces provisions for emerging technologies, strengthens post-market controls, and brings Ecuador's requirements more closely into alignment with international standards.

The 2026 Regulatory Overhaul

On April 28, 2026, ARCSA signed a new resolution that fundamentally replaces the regulatory framework that had been in place since 2016 under Resolution ARCSA-DE-026-2016-YMIH (as amended by ARCSA-DE-030-2018-JCGO). The resolution was signed by ARCSA Executive Director Dr. Daniel Antonio Sanchez Procel.

This is not a minor amendment or incremental update. It is a comprehensive regulatory overhaul that touches every aspect of the medical device registration and oversight process. Here is what changed and why it matters.

Key Changes Introduced by the 2026 Regulations

1. Explicit AI and ML-Enabled Device Provisions

For the first time, Ecuador's regulatory framework explicitly addresses artificial intelligence and machine learning-enabled medical devices. The new regulations establish requirements for software-as-a-medical-device (SaMD) products that incorporate AI/ML algorithms, including documentation requirements for algorithm transparency, training data validation, and performance monitoring protocols. This brings Ecuador into a small group of Latin American regulators that have formally addressed AI in medical devices, ahead of many regional peers.

2. Mandatory Technovigilance System

The 2026 regulations establish Ecuador's National Technovigilance System as a mandatory framework for adverse event reporting. All medical device registration holders are now required to report adverse events and field safety corrective actions through this system. This was previously a gray area — the 2016 regulations mentioned post-market surveillance but did not codify specific adverse event reporting obligations with the clarity and structure now in place.

3. Two-Tier Post-Market Control

The new regulations introduce a structured two-tier post-market control system:

• Tier 1 — Visual inspections: ARCSA conducts visual inspections of medical device labeling, packaging, storage conditions, and documentation at points of entry and distribution. This is a documentation and visual conformity check.
• Tier 2 — Laboratory analysis: ARCSA may require physical samples of devices to be submitted for laboratory testing and analysis. This is triggered when there are concerns about product quality, safety signals, or as part of routine surveillance for higher-risk device classes.

This structured approach replaces the previous ad hoc inspection system and gives ARCSA clearer enforcement tools.

4. Enhanced Traceability Requirements

The 2026 regulations codify traceability requirements using GS1 barcode identification and batch-level traceability. Registration holders must ensure that their devices can be tracked through the entire supply chain, from manufacturing through distribution to the point of use in healthcare facilities.

5. Sanctions Under Organic Health Law

Non-compliance with the new regulations is explicitly subject to sanctions under Ecuador's Organic Health Law. This gives the new requirements teeth — violations can result in product seizure, registration suspension or cancellation, fines, and in severe cases, criminal liability.

6. Modernized Documentation Standards

The new regulations update and expand the required documentation for registration applications, bringing the requirements closer to the standards expected by IMDRF-member regulators. This includes more detailed requirements for clinical and preclinical data, quality system documentation, and Declaration of Conformity content.

What This Means for Manufacturers

If you are already registered in Ecuador under the 2016 regulations, your existing registrations remain valid until their natural expiration (5-year validity period). However, any new registrations, renewals, or significant amendments must comply with the 2026 framework. If you are entering Ecuador for the first time, you will be working entirely under the new rules.

The practical impact of these changes is significant: Ecuador has moved from a relatively passive regulatory posture to one with active post-market surveillance, mandatory adverse event reporting, and explicit provisions for emerging technologies. Manufacturers who treat Ecuador as a "rubber stamp" market will find that the 2026 regulations demand genuine compliance effort.

Recommended Reading

UK MHRA 2026 Regulatory Overhaul: CE Mark Recognition, DORS Fees, Clinical Trials Framework, and What Manufacturers Must Do

Regulatory Quality Systems2026-05-17 · 13 min read

Definition of Medical Devices in Ecuador

Under Ecuadorian law (Reglamento Para El Registro y Control Sanitario de Dispositivos Medicos, reactivos Bioquimicos y Diagnostico y Productos Dentales, Art. 2), a medical device is defined as any article, instrument, apparatus, appliance, or mechanical invention -- including its components, parts, or accessories -- manufactured, sold, or recommended for use in:

• Diagnosis, cure, or palliative treatment of a disease, disorder, or abnormal physical state or its symptoms
• Replacement or modification of anatomy or a physiological process
• Disease prevention or control

The definition also includes amalgams, varnishes, sealants, and similar products. Ecuadorian regulations further categorize medical devices by duration of body contact:

Duration Category	Definition
Transient use	Intended for continuous use for less than 60 minutes
Short-term use	Intended for continuous use for up to 30 days
Long-term use	Intended for continuous use for more than 30 days

This duration framework is consistent with the principles used by IMDRF-member regulators and directly influences the risk classification assigned to a device.

Device Classification

Ecuador uses a four-tier risk-based classification system for medical devices, consistent with the IMDRF (formerly GHTF) framework. This system is nearly identical to the classification schemes used in Australia, Brazil, and many other jurisdictions that follow the IMDRF model.

The classification rules for medical devices are laid down in Article 16 of the Reglamento y Control Sanitario de Dispositivos Medicos y Dentales (2009). In vitro diagnostic (IVD) products are divided into the same four classes (I through IV), but the classification rules for IVDs are defined separately in Article 23 of the same regulation. If you are registering an IVD product, be aware that ARCSA applies distinct classification criteria specific to diagnostic devices.

Classification Table

Class	Risk Level	Description	Examples
Class I	Low risk	Non-invasive devices or devices that contact the body surface only; failure unlikely to cause serious harm	Bandages, tongue depressors, manual surgical instruments, hospital beds, examination gloves, wheelchairs
Class II	Moderate risk	Devices that may enter the body through natural orifices or contact the body for limited duration, with moderate complexity	Hypodermic needles, surgical sutures, contact lenses, blood pressure monitors, powered surgical instruments, some diagnostic devices
Class III	High risk	Devices that penetrate the body through surgical intervention, are implanted, or present significant complexity; includes most life-supporting and life-sustaining devices	Orthopedic implants, cardiac catheters, dialysis equipment, ventilators, infusion pumps, intraocular lenses
Class IV	Critical risk	Devices implanted in direct contact with the heart, central nervous system, or central circulatory system; devices incorporating biological materials or medicinal substances; devices where failure would cause death or serious injury	Cardiovascular stents, pacemakers, heart valves, defibrillators, spinal cord stimulators, devices incorporating medicinal substances

Classification Principles

ARCSA applies the following principles when determining device classification:

• Duration of body contact — Devices intended for continuous use (more than 30 days) are generally classified higher than those for transient or short-term use.
• Invasiveness — Surgically invasive devices receive higher classification than non-invasive devices.
• Clinical significance — Devices that are life-supporting or life-sustaining are classified in Class III or IV.
• Anatomical location — Devices contacting the central circulatory system or central nervous system are classified as Class IV.
• Incorporation of medicinal substances or biological materials — Devices incorporating drugs or biological materials receive higher classification.
• Technology complexity — Under the 2026 regulations, devices incorporating AI or ML algorithms may receive higher classification depending on the clinical significance of the algorithm's role in the diagnostic or therapeutic function.

When a device could fall into multiple classes based on different classification rules, the highest applicable class governs.

Practical tip: Because Ecuador's classification system follows the IMDRF framework, it is broadly consistent with the systems used in Australia (TGA), Brazil (ANVISA), and many ASEAN countries. If you have classified your device for any of these markets, that classification provides a reliable starting point for Ecuador. However, always verify classification with ARCSA or your authorized representative, as borderline cases may be interpreted differently.

IVD-Specific Classification

In vitro diagnostic (IVD) products are subject to the same four-class system (I through IV), but are classified under separate rules defined in Article 23 of the Reglamento y Control Sanitario de Dispositivos Medicos y Dentales (2009). These IVD-specific classification rules consider factors such as:

• Whether the IVD is intended for self-testing by lay persons
• Whether the IVD is intended for near-patient (point-of-care) testing
• Whether the IVD is a companion diagnostic
• Whether the IVD is used for screening of blood or tissue donations
• Whether the IVD detects infectious agents with a high risk of transmission

Under the 2026 regulations, ARCSA has also introduced a new definition for "Research Use Only" (RUO) products, which are now explicitly regulated. RUO products intended solely for scientific or technological research require specific documentation -- including manufacturer certifications, technical inserts, and ethical approval from research committees (Comite de Etica de Investigacion en Seres Humanos, CEISH) -- to ensure they are not used for clinical or diagnostic purposes.

Registration Process Step-by-Step

The ARCSA registration process follows a defined sequence. Here is a detailed walkthrough for foreign manufacturers.

Step 1: Determine Device Classification

Classify your device according to Ecuador's four-tier risk system (Class I, II, III, or IV). Your existing classification from other IMDRF-aligned jurisdictions provides a useful reference, but should be confirmed against Ecuador's specific rules. Classification determines the depth of technical review, documentation requirements, and the overall timeline.

Step 2: Appoint an Authorized Representative

Foreign manufacturers must appoint an Authorized Representative (Representante Autorizado) in Ecuador. This is a mandatory legal requirement. The Authorized Representative acts as the liaison between the manufacturer and ARCSA for all regulatory matters, including application submission, correspondence, and post-market obligations.

The Authorized Representative must:

• Be domiciled in Ecuador
• Hold a valid operating permit (permiso de funcionamiento) issued by ARCSA
• Have the legal capacity to represent the foreign manufacturer before ARCSA
• Accept responsibility for regulatory compliance during the registration validity period

Step 3: Obtain an Operating Permit

The applicant (or the Authorized Representative acting on the manufacturer's behalf) must hold a valid operating permit from ARCSA. This permit authorizes the entity to engage in the importation, distribution, or commercialization of medical devices in Ecuador.

Step 4: Prepare the Technical Documentation

Compile the complete documentation package required for registration. This includes all items listed in the Required Documentation section below. Under the 2026 regulations, the documentation standards have been updated and expanded — ensure you are working from the current requirements, not the 2016 checklist.

Step 5: Submit the Application

Submit the registration application to ARCSA through the Ventanilla Unica Ecuatoriana (VUE), Ecuador's official online platform for regulatory submissions. The application must include all required documents, the completed application form, and proof of fee payment (processed via an official payment order within the VUE system). ARCSA conducts an initial administrative review to verify completeness before proceeding to technical evaluation. If deficiencies are found during the administrative review, the applicant is given a defined window to correct and resubmit.

Step 6: Technical Evaluation

ARCSA reviews the technical documentation to assess whether the device meets the requirements for safety and performance. The depth and duration of this review depend on the device classification:

• Class I and II: Simplified review, potentially qualifying for the simplified route if the device holds a certificate from a recognized country
• Class III and IV: Full technical evaluation including review of clinical data, risk assessments, and quality system documentation

Step 7: Additional Information Requests

ARCSA may issue requests for additional information during the technical evaluation. The applicant must respond within the timeframe specified by ARCSA. Failure to respond in a timely manner can result in application rejection.

Step 8: Registration Certificate Issuance

Upon successful completion of the technical evaluation, ARCSA issues the sanitary registration certificate (Registro Sanitario). The certificate is valid for 5 years and must be renewed before expiration to maintain market access.

Step 9: Post-Market Compliance

After registration, the manufacturer and Authorized Representative must comply with all post-market obligations under the 2026 regulations, including technovigilance reporting, traceability requirements, and cooperation with ARCSA inspections.

Recommended Reading

FDA Weight Loss Device Guidance 2026: Premarket Considerations, Clinical Evidence, and Benefit-Risk Framework

Regulatory Clinical Evidence2026-05-17 · 11 min read

Required Documentation

The 2026 regulations specify the following documentation requirements for medical device registration applications. All documents must be submitted in Spanish or accompanied by certified Spanish translations.

Document	Description
Appointment of Authorized Representative	Legal document formally appointing the Ecuador-based representative, including scope of authority and duration
Authorization from Product Owner	If the applicant is not the original manufacturer, a written authorization from the product owner granting the right to register the device in Ecuador
Applicant's Operating Permit	Copy of the ARCSA-issued operating permit (permiso de funcionamiento) for the applicant or authorized representative
List of Devices	Complete list of devices included in the application, with trade names, models, classification, and intended use for each
Fee Payment Receipt	Proof of payment of the applicable ARCSA registration fee
Certificate of Free Sale (CFS) / Free Sales Certificate	A CFS or equivalent document issued by a competent health authority in the country of origin, confirming the device is authorized for sale in that country
Quality System Certification	Evidence of compliance with an internationally recognized quality management system standard (e.g., ISO 13485 certification). Under the 2025 US-Ecuador trade framework, ARCSA accepts MDSAP audit reports from US facilities
Declaration of Conformity	A formal Declaration of Conformity issued by the manufacturer, attesting that the device meets applicable safety and performance requirements
Device Description and Intended Use	Detailed technical description of the device, including its design, materials, principle of operation, and intended use / indications for use
Clinical and Preclinical Data	Clinical evaluation data, preclinical test results, and/or published literature supporting the safety and performance of the device. The depth of data required increases with risk class

Detailed Technical File Checklist

Below is the detailed list of technical documentation items that ARCSA expects as part of a complete registration application. While the table above summarizes the core categories, the following checklist reflects the specific documents that experienced regulatory consultants prepare for Ecuadorian submissions:

• Quality reports — Issued by the manufacturer, including signature, name, and position of the responsible person
• Sterility reports — Issued by the manufacturer (for sterile devices), including signature, name, and position of the responsible person
• Finished product specifications — Complete specifications for the finished device
• Product description — Detailed description of functional components, parts, and structure, including lists, diagrams, images, or drawings of functional components
• Raw materials description — Description and specifications of all raw materials used in manufacturing
• Stability reports — Signed by the responsible person who carried out the tests, demonstrating shelf-life and storage conditions
• Batch and series code interpretation — Explanation of the batch/lot coding system, with signatures, names, and positions of responsible persons
• Labels and instructions for use — Complete label artwork and IFU in Spanish. Labels must include the product name, brand name, and packaging contents (per Reglamento y Control Sanitario de Dispositivos Medicos y Dentales, Art. 14)
• Primary and secondary packaging specifications — Description and technical specifications of both primary and secondary packaging
• Manufacturing process description — Including a flow chart of the manufacturing process for the medical device
• Biofunctionality reports — Demonstrating the functional performance of the device
• IEC 60601 certificates — For electrically powered medical devices, demonstrating electrical safety and electromagnetic compatibility
• Biocompatibility studies — Based on ISO 10993, for devices that contact the body
• Scientific evaluation of the product — Literature review and scientific assessment supporting safety and efficacy

Practical tip: Under the 2026 regulations, the quality system certification requirement is more rigorously enforced than under the previous framework. If you hold ISO 13485 certification, ensure the certificate covers the specific devices you are registering and that it is issued by a recognized conformity assessment body. For US manufacturers, MDSAP audit reports are accepted and can streamline this requirement. Note also that copies of GMP and quality system certificates must be notarized, and certain documents may require legalization by an Ecuadorian diplomatic mission (embassy or consulate) in the country of origin.

Additional Documentation for Higher-Risk Devices

For Class III and IV devices, ARCSA may also require:

• Risk analysis — A comprehensive risk analysis conducted in accordance with ISO 14971 or an equivalent standard
• Clinical investigation reports — Full clinical study reports for devices where clinical investigations have been conducted
• Biocompatibility data — Biocompatibility assessment for devices that contact the body, in accordance with ISO 10993
• Sterilization validation — For devices supplied sterile, validation of the sterilization process
• Software documentation — For devices incorporating software (including AI/ML algorithms under the 2026 regulations), documentation of the software development lifecycle, verification and validation activities, and algorithm performance data
• Electrical safety and electromagnetic compatibility — Test reports demonstrating compliance with applicable IEC standards for electrically powered devices

Simplified Route for Recognized Certificates

One of the most practical features of Ecuador's registration system is the simplified route for devices that hold certificates from recognized regulatory authorities. This pathway can significantly reduce both the timeline and the documentation burden.

Eligibility

Class I and Class II devices that are already approved or cleared by one of the following recognized regulatory authorities may qualify for simplified registration:

• United States — FDA 510(k) clearance or PMA approval
• European Union — CE marking under the EU MDR or EU IVDR
• Canada — Health Canada Medical Device License (MDL)
• Australia — TGA inclusion in the Australian Register of Therapeutic Goods (ARTG)
• Japan — PMDA approval
• South Korea — MFDS approval

What Simplified Registration Means

Under the simplified route:

• Reduced documentation — ARCSA may accept the certificate from the recognized authority as evidence of safety and performance, reducing the need to submit duplicate clinical and preclinical data
• Shorter review timeline — Applications under the simplified route are typically processed faster, often within 2-3 months
• Lower technical scrutiny — ARCSA places greater weight on the assessment already conducted by the recognized authority, focusing its own review on local compliance aspects such as labeling in Spanish and authorized representative arrangements

Required Evidence for Simplified Route

To use the simplified route, you must provide:

1. A copy of the valid certificate, clearance, or approval from the recognized authority
2. Evidence that the device registered in the recognized country is identical to the device you are registering in Ecuador (same manufacturer, same design, same materials, same intended use)
3. Any conditions or restrictions imposed by the recognized authority, and how they are addressed for the Ecuadorian market

Practical tip: The simplified route is a significant advantage for manufacturers who already have FDA clearance or CE marking. If you have multiple recognized certificates, choose the one from the jurisdiction with the most rigorous review — a PMA approval from the FDA or a CE certificate under the EU MDR will carry more weight with ARCSA than approvals from less recognized authorities. However, note that the simplified route is only available for Class I and II devices. Class III and IV devices must go through the full technical evaluation regardless of existing certificates.

Authorized Representative Requirements

The appointment of an Authorized Representative is a mandatory requirement for all foreign manufacturers seeking to register medical devices in Ecuador. The Authorized Representative is the legal point of contact between the manufacturer and ARCSA and bears significant responsibilities.

Key Responsibilities

The Authorized Representative is responsible for:

• Application submission — Filing the registration application with ARCSA on behalf of the foreign manufacturer
• Regulatory correspondence — Receiving and responding to all communications from ARCSA, including requests for additional information
• Post-market obligations — Managing technovigilance reporting, field safety corrective actions, and compliance with post-market surveillance requirements
• Record keeping — Maintaining records of all regulatory activities, correspondence, and compliance documentation
• License management — Handling renewals, amendments, and transfers of the sanitary registration

Selection Criteria

When selecting an Authorized Representative in Ecuador, consider the following:

• Regulatory experience — Choose a representative with demonstrated experience in medical device registration with ARCSA. The 2026 regulations introduce new requirements that demand familiarity with the updated framework.
• Operating permit status — Verify that the representative holds a valid ARCSA operating permit and is in good standing.
• Technical capability — Ensure the representative has the technical capacity to manage post-market obligations, including adverse event reporting through the National Technovigilance System.
• Communication — Given that all regulatory correspondence is in Spanish, the representative must have strong bilingual capabilities if your team does not speak Spanish.
• Geographic presence — While ARCSA is based in Quito, the representative should be able to manage interactions with ARCSA efficiently regardless of their physical location within Ecuador.

Changing Authorized Representatives

It is possible to change your Authorized Representative during the validity period of a registration. This requires filing an amendment with ARCSA and providing documentation of the new appointment. Plan any changes carefully to avoid gaps in representation that could affect your compliance status.

Recommended Reading

FDA Third Party Review Program Due-Diligence Checklist: How to Decide Whether 3P510k Is Right for Your 510(k) Submission

510(k) Regulatory2026-05-05 · 19 min read

Fees and Timeline

Government Fees

ARCSA charges the following fees for medical device registration activities:

Activity	Fee (USD)
New product registration	$905
License amendment	$95
License renewal	$185

These are government fees paid directly to ARCSA. They do not include costs for authorized representative services, translation, document preparation, quality system certification, or other expenses associated with the registration process.

Registration Timeline

The overall timeline from application submission to registration certificate issuance depends on the device classification and the chosen pathway:

Pathway	Typical Timeline
Simplified route (Class I/II with recognized certificate)	2-3 months
Standard route (Class I/II without recognized certificate)	3-4 months
Full technical review (Class III)	4-6 months
Full technical review (Class IV)	5-6 months

These timelines are approximate and can be affected by:

• Completeness of the application — Incomplete applications will be returned or result in additional information requests, adding weeks or months to the process
• ARCSA workload — Processing times can vary based on the volume of applications ARCSA is handling at any given time
• Complexity of the device — Novel devices, AI/ML-enabled devices, and devices with complex clinical data may require longer review periods
• Timeliness of responses — Delays in responding to ARCSA requests for additional information will extend the timeline

License Validity and Renewal

Sanitary registration certificates are valid for 5 years from the date of issuance. Renewal applications should be submitted before the expiration date to ensure continuous market access. The renewal process requires updated documentation and the renewal fee of USD 185.

License Transfer

License transfer is possible under the 2026 regulations and is treated as a minor change. This means that if you change your authorized representative, transfer the registration to a different local entity, or restructure your commercial arrangements, the transfer can be processed through the amendment pathway with the lower amendment fee of USD 95, rather than requiring a completely new registration.

Labeling and Language Requirements

Ecuador has specific requirements for medical device labeling that must be carefully addressed. All labeling and documentation must be in Spanish.

General Labeling Requirements

Medical device labels must include the following information in Spanish:

• Device name — The trade name and generic name of the device
• Manufacturer information — Name and address of the manufacturer
• Authorized representative information — Name and address of the Ecuador-based authorized representative
• Intended use / indications — Clear description of what the device is intended to do
• Instructions for use — Directions for proper use, including any warnings, contraindications, and precautions
• Storage conditions — Required storage temperature, humidity, and other environmental conditions
• Expiration date — Where applicable, the shelf life or expiration date of the device
• Batch or lot number — For traceability purposes
• Risk classification — The ARCSA risk class of the device
• Sanitary registration number — The ARCSA-issued registration number, once obtained

Spanish Language Requirement

All labeling, instructions for use, and regulatory documentation submitted to ARCSA must be in Spanish. For foreign manufacturers, this means:

• Labels must be printed in Spanish or include a Spanish-language insert
• Instructions for use (IFU) must be provided in Spanish
• All regulatory correspondence and submissions must be in Spanish
• Technical documentation may be submitted in English with certified Spanish translations

Traceability Labeling

Under the 2026 regulations, medical device labeling must support the traceability requirements using GS1 barcode identification. This means:

• Devices must carry GS1-compliant barcodes at the batch or lot level
• The barcode must encode sufficient information to trace the device through the supply chain
• Importers and distributors must maintain systems that can read and process the GS1 barcodes

Practical tip: The Spanish-language requirement is strictly enforced by ARCSA. Under the 2026 regulations, Tier 1 post-market inspections specifically check labeling compliance at the point of import and distribution. Non-compliant labeling is one of the most common reasons for regulatory action in Ecuador. Budget for professional translation and ensure that translations are technically accurate, not just literal translations of English-language content.

Post-Market Surveillance and Technovigilance

The 2026 regulations introduce the most significant changes to post-market requirements in Ecuador's history. These changes bring Ecuador closer to the post-market surveillance frameworks used by more mature regulators and impose meaningful obligations on registration holders.

Two-Tier Post-Market Control

The 2026 regulations establish a structured two-tier post-market control system:

Tier 1: Visual Inspections

ARCSA conducts visual inspections of medical devices at points of entry, at distribution facilities, and at healthcare facilities. These inspections focus on:

• Labeling compliance — Verifying that labels are in Spanish, contain all required information, and accurately reflect the registered device
• Storage conditions — Confirming that devices are stored under the conditions specified in the registration
• Documentation — Checking that the sanitary registration certificate, operating permits, and other required documentation are current and available
• Packaging integrity — Visual assessment of packaging condition and integrity

Tier 1 inspections are routine and may be conducted without prior notice. Registration holders should ensure that their authorized representatives and distribution partners are prepared for inspections at any time.

Tier 2: Laboratory Analysis

ARCSA may require physical samples of devices to be submitted for laboratory testing and analysis. This tier is triggered when:

• ARCSA identifies potential quality or safety concerns during a Tier 1 inspection
• Adverse event reports suggest a possible device defect
• Routine surveillance of higher-risk device classes (Class III and IV)
• ARCSA receives intelligence about potential non-compliance

Under Tier 2, ARCSA may test devices for:

• Conformance to the technical specifications declared in the registration
• Biocompatibility and material safety
• Sterility assurance (for sterile devices)
• Electrical safety and electromagnetic compatibility (for electrically powered devices)
• Software functionality and cybersecurity (for devices incorporating software, including AI/ML-enabled devices under the new regulations)

Mandatory Adverse Event Reporting

The 2026 regulations establish mandatory adverse event reporting through Ecuador's National Technovigilance System. This is a new requirement that codifies obligations that were previously unclear under the 2016 framework.

Registration holders must report:

• Serious adverse events — Any event that results in death, life-threatening condition, hospitalization, disability, or the need for medical or surgical intervention to prevent permanent impairment
• Field safety corrective actions — Any recall, modification, or advisory notice issued for the device in Ecuador or any other market where the device is sold
• Near-miss events — Events that could have resulted in a serious adverse event but did not due to timely intervention

Reporting must be done through ARCSA's designated reporting channels within the timeframes specified by the National Technovigilance System. Failure to report adverse events is subject to sanctions under the Organic Health Law.

Traceability Requirements

The 2026 regulations mandate GS1 barcode identification and batch-level traceability throughout the supply chain. Registration holders must:

• Ensure devices carry GS1-compliant barcodes encoding device identification and batch/lot information
• Maintain records that allow the device to be traced from manufacturing through distribution to the point of use
• Be able to provide traceability information to ARCSA upon request, particularly in the context of adverse event investigations or recalls
• Support recall operations if a field safety corrective action is required

Sanctions for Non-Compliance

Non-compliance with the post-market surveillance requirements is subject to sanctions under Ecuador's Organic Health Law. Potential consequences include:

• Product seizure and destruction
• Suspension or cancellation of the sanitary registration
• Monetary fines
• Import bans
• In severe cases involving fraud or deliberate concealment of safety information, criminal liability

The 2026 regulations significantly strengthen ARCSA's enforcement tools compared to the 2016 framework. The combination of mandatory technovigilance reporting, structured post-market inspections, and explicit sanctions means that compliance is no longer optional or aspirational — it is an enforceable legal obligation.

Recommended Reading

Ambulatory Surgery Center Expansion 2026: CMS OPPS/ASC Final Rule, 573 New Procedures, and Medical Device Commercialization Strategy

Reimbursement & Market Access Commercialization2026-05-16 · 11 min read

Tips for Foreign Manufacturers

1. Leverage Existing Registrations

If your device is already cleared or approved in the United States, European Union, Canada, Australia, Japan, or South Korea, use the simplified registration route for Class I and II devices. This can reduce your timeline from 4-6 months to 2-3 months and significantly reduce the documentation burden. Prepare certified copies of your FDA clearance letter, CE certificate, or equivalent documentation in advance.

2. Choose Your Authorized Representative Carefully

Your Authorized Representative is your legal face in Ecuador. They will receive all ARCSA correspondence, manage adverse event reporting obligations, and handle renewals and amendments. Choose a representative with specific medical device regulatory experience — not just general import/export logistics. Under the 2026 regulations, the representative's role in technovigilance reporting is critical, and an inexperienced representative can expose you to compliance risk.

3. Budget for Translation

All labeling, instructions for use, and regulatory submissions must be in Spanish. Professional, technically accurate translation is essential. Poor translations lead to ARCSA requests for additional information, delays, and potential labeling non-compliance detected during Tier 1 inspections. Use translators with medical device expertise, not general-purpose translation services.

4. Prepare for the 2026 Requirements

The 2026 regulations introduce new requirements that did not exist under the 2016 framework. If you are registering for the first time, ensure your documentation package addresses:

• AI/ML algorithm documentation (if applicable)
• GS1 barcode and traceability documentation
• Adverse event reporting procedures aligned with the National Technovigilance System
• Quality system evidence that meets the updated standards

If you are renewing an existing registration, you will need to demonstrate compliance with the new requirements at the time of renewal.

5. Consider Ecuador as Part of a Regional Strategy

Ecuador is a member of the Andean Community (CAN), and ARCSA's classification system is aligned with the IMDRF framework used by regulators across Latin America. Documentation prepared for Ecuador — particularly classification rationale, technical file content, and clinical evaluation reports — can be adapted for registration in Colombia, Peru, and other regional markets with relatively modest additional effort.

6. Understand the MDSAP Advantage

Under the 2025 US-Ecuador trade framework, ARCSA accepts MDSAP audit reports from US facilities as evidence of quality system compliance. If your facility has undergone an MDSAP audit, this can streamline the quality system documentation requirement in your registration application. This is a meaningful advantage for US manufacturers that did not exist prior to the trade framework.

7. Plan for Post-Market Obligations from Day One

The 2026 regulations make post-market compliance a central part of the regulatory framework. Do not treat registration as the finish line. Before your device enters the Ecuadorian market, ensure you have:

• Procedures for adverse event identification, evaluation, and reporting through the National Technovigilance System
• Systems for GS1 barcode-compliant traceability
• A distribution network that can support Tier 1 visual inspections and Tier 2 sample collection
• A plan for field safety corrective actions, including recall logistics

8. Maintain Accurate and Complete Records

ARCSA may request documentation at any time during the 5-year validity period of your registration. Maintain complete, organized records of your registration application, all correspondence with ARCSA, adverse event reports, quality system certificates, and distribution records. Good record-keeping is the foundation of post-market compliance.

9. Monitor Regulatory Updates

The 2026 overhaul demonstrates that ARCSA is actively modernizing its regulatory framework. Additional implementing regulations, guidance documents, and procedural updates are likely to follow. Work with your Authorized Representative to stay informed of changes that may affect your registrations.

10. Factor Ecuador into Your Global Regulatory Timeline

With registration timelines of 2-6 months depending on risk class and pathway, Ecuador can be incorporated into a global market entry timeline relatively efficiently. Class I and II devices with recognized certificates can be registered in as little as 2-3 months, making Ecuador one of the faster Latin American markets for lower-risk products. Class III and IV devices require longer, but the timelines are reasonable compared to many regulators in the region.

11. Understand Ecuador's Market Dynamics

Several Ecuador-specific factors affect your commercial strategy beyond the regulatory process:

• Public procurement dominance — Ecuador's public health system, led by IESS and MSP, is the largest single buyer of medical devices. Market access largely depends on successful participation in government tenders, where price is a decisive factor. Factor public procurement requirements into your pricing and distribution strategy from the outset.
• Dollarized economy — Ecuador uses the US dollar as its official currency, which eliminates exchange rate risk for US manufacturers. However, it can limit pricing flexibility in the face of imported inflation and makes cost competitiveness particularly important.
• Distribution concentration — Commercial activity and healthcare infrastructure are concentrated in Quito and Guayaquil. Effective penetration into other provinces requires additional logistics investment and channel development.
• CAN harmonization — As an active participant in the Andean Community (CAN), Ecuador regularly adopts the bloc's harmonized technical resolutions for medical devices. Monitoring CAN developments can help anticipate national regulatory changes before they are formally enacted.
• Regulatory environment in transition — ARCSA is actively working to enhance its capacity and standardize processes. Companies may face some uncertainties due to evolving rule interpretation and enforcement, particularly during the transition from the 2016 framework to the 2026 regulations.

12. Ensure Proper Document Legalization

Foreign documents submitted to ARCSA -- including Certificates of Free Sale, GMP/ISO certificates, and authorizations -- must be properly legalized. In practice, this means:

• Copies of GMP certificates and ISO certificates must be notarized
• Certain documents may require legalization (apostille or consular legalization) by an Ecuadorian diplomatic mission in the country of origin
• All documents must be submitted in Spanish or accompanied by certified Spanish translations

Budget time and cost for the document legalization process, which can add several weeks to your preparation timeline.

---

Ecuador's medical device regulatory framework has undergone a fundamental transformation with the April 2026 regulations. The new framework replaces rules that had been in place since 2016, introduces explicit provisions for AI and ML-enabled devices, establishes mandatory technovigilance reporting, creates a structured two-tier post-market control system, and brings Ecuador's requirements into closer alignment with international standards. For foreign manufacturers, Ecuador remains an accessible and attractive market — particularly for Class I and II devices that can leverage the simplified registration route using existing FDA, CE, or other recognized certificates. But the 2026 regulations demand genuine compliance effort, particularly in post-market surveillance, adverse event reporting, and traceability. Manufacturers who approach Ecuador with the same rigor they apply to larger markets will find a well-structured and increasingly modernized regulatory environment that supports long-term commercial success.